Surrozen Raises $60M in Stock Sale at 1.2% Discount to Thursday's Close
SRZN has more than doubled off its 52-week low of $12.12 on light trading volume (0.2× avg).
Summary
Surrozen priced 1,894,540 new shares at $31.67 apiece for $60M gross, roughly a 1% discount to the $32.05 last price. The raise is modest next to the company's market value but adds meaningful cash to a balance sheet that has leaned on its $50M at-the-market program and the $95.1M final tranche of its March 2025 private placement, which closed October 20. The new shares dilute existing holders, and the release does not disclose the pre-offering share count. Closing is expected on or about November 16, subject to customary conditions. Q3 results filed November 9 showed a $129.7M net loss, $113.0M of it non-cash warrant and tranche remeasurement, alongside the Boehringer Ingelheim arbitration disclosure.
At the time of this announcement, SRZN was trading at $32.05 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $603.7M. The 52-week trading range was $12.12 to $37.83. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Wiseek News.